9月22日，西陇科学(002584.SZ)发布公告称，实际控制人黄伟波、黄伟鹏、黄侦凯、黄侦杰计划通过集中竞价及大宗交易方式减持合计不超过1755.64万股 （占总股本3%），按当日收盘价9.45元/股计算，套现金额约为1.7亿元。 限公司未完成业绩承诺，西陇科学为可能承担的业绩承诺补偿义务计提预计负债。 公告提示，若本次披露的股份全部减持完毕，以上实际控制人及一致行动人仍将继续持有西陇科学22.61%股份，不会导致控制权发生变更，不会对治理结 构和持续经营产生不利影响。 公开信息显示，黄少群、黄伟波、黄伟鹏系兄弟关系，黄侦凯、黄侦杰系黄伟波之子。 西陇科学主营业务为化学试剂的研发、生产、销售，以及原料药及食品添加剂生产、销售，并从事部分化工原料贸易等业务，主要产品为化学试剂、光伏及 新能源材料、原料药及医药中间体、化工原料。 半年报显示，2025年上半年，西陇科学实现营收入33.68亿元，同比下降14.78%；实现净亏损7531.73万元，同比由盈转亏；实现扣非净利润3957.6万元，同 比下降3.90%。西陇科学营收下降主要系化工原料贸易营业收入和专用化学品营业收入减少；净利润亏损主要系转让控股权的子公司 ...

Core Viewpoint - The stock of Xilong Science increased by 2.45% today, with a turnover rate of 28.84% and a trading volume of 1.319 billion yuan, indicating significant trading activity and interest in the stock [2]. Trading Activity - The stock was listed on the Dragon and Tiger list due to its turnover rate reaching 28.84%, with institutional investors net selling 17.9684 million yuan [2]. - The top five trading departments accounted for a total transaction volume of 236 million yuan, with a net buying amount of 3.6192 million yuan [2]. - Among the trading departments, two institutional special seats were involved, with total buying amounting to 21.724 million yuan and selling amounting to 39.6924 million yuan, resulting in a net sell of 17.9684 million yuan [2]. Fund Flow - The stock experienced a net inflow of 479,700 yuan from major funds today, with a significant inflow of 32.7653 million yuan from large orders, while large orders saw a net outflow of 32.2856 million yuan [3]. - Over the past five days, the stock has seen a net inflow of 224 million yuan from major funds [3]. Historical Performance - In the past six months, the stock has appeared on the Dragon and Tiger list five times, with an average price drop of 0.38% the day after being listed and an average increase of 1.70% over the following five days [3].

Core Viewpoint - The company, Xilong Science, engaged with investors during the 2025 Guangdong Investor Collective Reception Day, discussing its business layout, product applications, and project progress [1][2]. Group 1: Business and Product Overview - Xilong Science has established a strategic layout in semiconductor new materials, including wet electronic chemical blending workshops, stripping liquid production lines, etching liquid production lines, ultra-pure reagents, and semiconductor material workshops [3]. - The company sells solid electrolyte materials, such as sulfides, through its official e-commerce platform "Youliao.com," with applications varying based on customer usage scenarios [3]. - The phosphate iron lithium cathode materials produced by the company are applicable in power batteries and energy storage batteries [3]. - Silver powder produced by the company is utilized in the photovoltaic sector [3]. - The company's electronic chemicals for the PCB sector include general types like acids, bases, and solvents, as well as functional wet electronic chemicals such as etching liquids, stripping liquids, and deburring liquids [3]. Group 2: Project Progress and Financial Performance - The first phase of the phosphate iron lithium cathode materials project has been completed and put into production [3]. - From January to June 2025, the revenue from lithium battery cathode materials reached 134,612,912.47 yuan, representing a significant increase compared to the same period last year [3]. - The second phase of the project, with a capacity of 30,000 tons, will be developed based on market demand and development planning, with timely disclosures to be made if information disclosure requirements are met [3]. - Regarding performance commitment compensation, the company disclosed on April 30, 2025, that it is not expected to pay additional cash compensation, with the remaining equity transfer payment and the value of the remaining equity in the target company expected to cover the performance compensation cap [3].

Group 1: Company Overview - The company is West Long Science Co., Ltd., with stock code 002584 [1] - The company specializes in the research, production, and sales of chemical reagents, raw materials, and food additives [2] Group 2: Strategic Layout - The company has established a strategic layout in the semiconductor new materials industry, including wet electronic chemical blending workshops and high-purity reagent production lines [2] - The company offers customized chemical services and has a clean packaging area [2] Group 3: Product Applications - Phosphate lithium cathode materials produced by the company can be used in both power batteries and energy storage batteries [3] - Silver powder produced by the company is applicable in the photovoltaic field [4] - The company's electronic chemicals include general electronic chemicals and functional wet electronic chemicals for PCB applications [5] Group 4: Financial Performance - For the first half of 2025, the revenue from lithium battery cathode materials reached approximately ¥134.61 million, a significant increase compared to the previous year [5] - The company reported an estimated performance compensation amount of ¥115.03 million related to the transfer of subsidiary equity [6] - The company has accounted for a provision of approximately ¥70 million for performance compensation, which will not adversely affect future operational performance [6]

Group 1 - The core point of the article is that Xilong Science Co., Ltd. has won a bid for chemical reagents from Sinopec (Dalian) Petrochemical Research Institute, indicating a successful procurement process [1][2] - The procurement announcement was published on August 24, 2025, and the project is located in Liaoning Province [2] - Xilong Science Co., Ltd. has made investments in 26 companies and participated in 1,658 bidding projects, showcasing its active engagement in the industry [1] Group 2 - The company holds 298 trademark registrations, 90 patents, and 10 copyrights, reflecting its strong intellectual property portfolio [1] - Additionally, Xilong Science has obtained 60 administrative licenses, indicating compliance with regulatory requirements [1]

Core Viewpoint - The development of China's chemical reagent industry has evolved from reliance on imports to gradual self-sufficiency, transitioning from low-end general reagents to high-end specialized reagents, with significant growth projected in market size [1][8]. Group 1: Industry Definition and Classification - Chemical reagents are refined fine chemical products derived from industrial-grade chemicals, classified by usage into general chemical reagents, PCB chemical reagents, and ultra-pure reagents, and by purity levels ranging from experimental pure (≥90%) to high purity (≥99.99%) [2][10]. Group 2: Current Development Status - The chemical reagent industry in China has undergone five stages: initial stage, developmental stage, reform and opening-up stage, rapid development stage, and mature development stage, with the current market becoming increasingly competitive [5][7]. Group 3: Market Size and Growth - The market size of China's chemical reagent industry is expected to grow to 240 billion yuan in 2024, an increase of 18.6 billion yuan from 2023, and is projected to reach 260 billion yuan by 2025 [1][8]. Group 4: Industry Chain - The chemical reagent industry is a crucial branch of laboratory supplies and fine chemicals, with the upstream including chemical raw materials, packaging materials, and equipment; the midstream focusing on research and production; and the downstream applications spanning various fields such as pharmaceuticals, new materials, and environmental protection [10][12]. Group 5: Competitive Landscape - The global chemical reagent market is dominated by foreign companies, with major players including Sigma-Aldrich, Thermo Fisher Scientific, and Cayman Chemical, which collectively hold over 80% of the market share in China's research reagent market [14][15]. Group 6: Development Trends - The industry is experiencing transformation driven by technological advancements, with increasing demand for high-performance chemical reagents, particularly in the fields of biotechnology, pharmaceuticals, electronics, and new energy [18][19][20]. - Environmental sustainability is becoming a key trend, prompting the development of green chemical reagents that meet environmental standards [18].

Core Viewpoint - West Long Science Co., Ltd. announced the release and new pledge of shares by its actual controller, Huang Shaoqun, indicating personal funding needs while emphasizing that this will not adversely affect the company's operations or governance [3][4]. Group 1: Share Pledge Details - Huang Shaoqun released 10,250,000 shares, accounting for 18.14% of his holdings and 1.75% of the company's total share capital, with the release date set for August 6, 2025 [3]. - He also pledged 10,860,000 shares, representing 19.22% of his holdings and 1.86% of the company's total share capital, starting from August 6, 2025 [3]. - As of the announcement date, Huang Shaoqun had a total of 33,390,000 shares pledged, with the cumulative pledge by him and his concerted actors accounting for 34.50% of his holdings and 8.83% of the company's total share capital [3]. Group 2: Regulatory Issues - On July 7, 2023, West Long Science received an administrative penalty from the Guangdong Securities Regulatory Bureau for information disclosure violations, resulting in a fine of 1.2 million yuan [4]. - The company was found to have inflated revenue and profits through fictitious trading activities involving ethylene glycol and methanol [4]. - Huang Shaoqun and other executives received individual fines ranging from 50,000 to 800,000 yuan for their roles in the violations [4]. Group 3: Company Overview and Financial Performance - West Long Science was established on July 19, 1994, with a registered capital of 5.852 billion yuan, focusing on the R&D, production, and sales of chemical reagents and raw materials [5][6]. - The company reported revenues of 6.183 billion yuan, 7.092 billion yuan, and 7.816 billion yuan for 2022 to 2024, reflecting year-on-year growth rates of 14.93%, 24.42%, and 10.22% respectively [6]. - The net profit attributable to shareholders for the same period was 88.05 million yuan, 33.35 million yuan, and 61.77 million yuan, with year-on-year changes of -52.93%, -62.56%, and 85.24% respectively [6]. - The company's asset-liability ratios were 53.46%, 50.64%, and 51.10% for the years 2022 to 2024 [6].

Group 1 - The company will announce the implementation of equity distribution and the adjustment of the conversion price for "Aladdin Convertible Bonds" on May 29, 2025 [1] - From May 28, 2025, until the equity distribution registration date, the "Aladdin Convertible Bonds" will suspend conversion, and conversion will resume on the first trading day after the registration date [1] - The profit distribution plan for the year 2024 includes a cash dividend of 1 yuan (before tax) for every 10 shares and a capital reserve increase of 2 shares for every 10 shares [1]

Group 1 - The company has successfully developed and produced a gold standard chromatographic solvent through upgrading its existing high-purity solvent production process, achieving significant reductions in metal ion content to the sub-ppb level and organic trace impurities to below 5 ppt [1][2] - The new solvent has been tested internally and meets or exceeds the performance indicators of imported brands from the US and Europe, demonstrating comparable or superior results in various analytical applications [2] - The product is primarily used in fields such as life sciences, pharmaceutical research, trace organic detection, food and drug safety testing, and environmental pollution detection [2] Group 2 - The successful development of the gold standard chromatographic solvent enriches the company's series of chromatographic chemicals and has led to preliminary bulk orders from domestic customers, which is expected to positively impact market expansion and performance growth [3]

本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融合 存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特 点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险及本 公司所披露的风险因素，审慎作出投资决定。 苏州昊帆生物股份有限公司 Suzhou Highfine Biotech Co., Ltd. （苏州高新区鸿禧路 32 号 F-12 标准厂房） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 苏州昊帆生物股份有限公司 招股说明书 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 苏州昊 ...